Side effects of regorafenib include pain, fatigue, diarrhea, nausea, high blood pressure, rash, dysphonia, and fever, and patients are advised to seek medical attention and reduce or discontinue the drug as prescribed. Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) who have received prior fluorouracil, oxaliplatin, and irinotecan-based chemotherapy, and who have received or are not candidates for anti-VEGF therapy, or anti-EGFR therapy (RAS wild type). Common adverse reactions to regorafenib include pain, fatigue, diarrhea, nausea, hypertension, rash, dysphonia, fever, hand-foot syndrome, mucositis, weight loss, anemia, infection, thrombocytopenia, lymphopenia, hypokalemia, hypokalemia, hypokalemia, hyponatremia, hypophosphatemia, hyperbilirubinemia, proteinuria, bleeding, and nephrotic syndrome. Serious adverse reactions include hepatotoxicity, hypertension, cardiac ischemia, myocardial infarction, and reversible posterior white matter encephalopathy syndrome. If patients have adverse reactions after taking the drug, it is recommended to consult a doctor in time, communicate with the doctor, and follow the doctor’s instructions to choose to reduce the dose of the drug or stop taking the drug, and patients with serious adverse reactions should be treated symptomatically depending on the individual situation. It is recommended that patients who are unwell go to regular hospitals in a timely manner and follow the doctor’s instructions for symptomatic treatment.